Filing Details

Accession Number:
0001599901-24-000075
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-05-21 17:05:29
Reporting Period:
2024-05-20
Accepted Time:
2024-05-21 17:05:29
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1599901 Avidity Biosciences Inc. RNA () DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1181556 A Arthur Levin C/O Avidity Biosciences, Inc.
10578 Science Center Drive, Suite 125
San Diego CA 92121
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-05-20 5,000 $1.24 19,830 No 4 M Direct
Common Stock Disposition 2024-05-20 5,000 $29.90 14,830 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2024-05-20 5,000 $0.00 5,000 $1.24
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
28,323 2030-02-18 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 253,872 Indirect By family trust
Footnotes
  1. The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 26, 2023.
  2. This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $29.23 to $30.36. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. All unexercised shares subject to the option are fully vested and exercisable as of the date hereof.